Key Takeaways
-
BioTissue has introduced CAM360 AG Dual Tabs to improve handling and preparation of its cryopreserved amniotic membrane therapy
-
The updated product retains the original ringless, hydrated, shelf-stable design and does not require refrigeration
-
The therapy is intended to support ocular surface healing in conditions including dry eye disease, superficial punctate keratitis, and neurotrophic keratitis
BioTissue has announced an updated dual-tab design for CAM360 AmnioGraft (CAM360 AG), its cryopreserved amniotic membrane therapy for mild to moderate ocular surface disease. The modification is intended to improve handling and preparation for eye care professionals while maintaining the tissue characteristics of the original product.
Introduced in 2024, CAM360 AG features a ringless, hydrated, shelf-stable design that eliminates the need for refrigeration. According to BioTissue, the updated CAM360 AG Dual Tabs incorporates feedback from eye care professionals to provide greater control during product preparation.
“CAM360 AG represented an important step forward in making our CAM therapies accessible to a broader range of patients, including those with mild to moderate ocular surface disease,” said Ted Davis, president and CEO, BioTissue. “Our ongoing partnerships with eye care professionals continue to shape how we advance our products. CAM360 AG Dual Tabs reflects that collaboration, translating insights from everyday clinical practice into meaningful product improvements that support practitioners and their patients.”
The updated product continues to use BioTissue's proprietary cryopreservation technology, which is designed to preserve the biological properties of amniotic membrane tissue. According to the company, cryopreserved amniotic membrane supports ocular surface healing through anti-inflammatory, anti-scarring, and anti-angiogenic mechanisms. The technology may be used in managing several ocular surface conditions, including dry eye disease, superficial punctate keratitis, and neurotrophic keratitis.